Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Healthcare | Biotechnology | Ireland
statements
Index- P/E- EPS (ttm)-1.25 Insider Own0.60% Shs Outstand156.46M Perf Week6.96%
Market Cap3.20B Forward P/E36.48 EPS next Y0.56 Insider Trans-36.52% Shs Float155.95M Perf Month10.28%
Income-196.60M PEG- EPS next Q-0.05 Inst Own95.50% Short Float3.91% Perf Quarter1.34%
Sales1.17B P/S2.73 EPS this Y-39.40% Inst Trans-1.38% Short Ratio3.78 Perf Half Y-6.16%
Book/sh6.88 P/B2.97 EPS next Y53.42% ROA-11.10% Target Price23.23 Perf Year-38.74%
Cash/sh3.42 P/C5.97 EPS next 5Y24.00% ROE-18.10% 52W Range16.65 - 37.75 Perf YTD0.15%
Dividend- P/FCF- EPS past 5Y-43.30% ROI-12.80% 52W High-46.58% Beta2.00
Dividend %- Quick Ratio2.20 Sales past 5Y13.60% Gross Margin84.60% 52W Low21.11% ATR1.00
Employees2235 Current Ratio2.50 Sales Q/Q30.70% Oper. Margin-15.00% RSI (14)59.39 Volatility8.74% 5.14%
OptionableYes Debt/Eq0.26 EPS Q/Q45.60% Profit Margin-16.80% Rel Volume1.01 Prev Close20.43
ShortableYes LT Debt/Eq0.25 EarningsFeb 13 BMO Payout- Avg Volume1.61M Price20.17
Recom2.80 SMA2010.44% SMA503.93% SMA200-3.85% Volume1,135,722 Change-1.30%
Feb-14-20Reiterated H.C. Wainwright Neutral $26 → $25
Feb-14-20Downgrade JP Morgan Overweight → Neutral $21
Feb-14-20Downgrade BofA/Merrill Buy → Neutral $31 → $20
Feb-06-20Initiated Mizuho Neutral
Jan-31-20Upgrade Wolfe Research Underperform → Peer Perform
Sep-05-19Upgrade Morgan Stanley Underweight → Equal-Weight $30 → $20
Jul-15-19Upgrade Goldman Sell → Neutral
May-31-19Initiated H.C. Wainwright Neutral
May-01-19Downgrade Citigroup Buy → Neutral
Dec-19-18Downgrade Goldman Neutral → Sell
Dec-14-18Initiated Wolfe Research Underperform
Dec-13-18Downgrade Credit Suisse Outperform → Underperform
Nov-05-18Initiated Piper Jaffray Neutral $40
Aug-07-18Initiated Stifel Hold $15 → $45
Jun-21-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jun-06-18Initiated B. Riley FBR, Inc. Buy $60
May-16-18Upgrade Citigroup Neutral → Buy
May-11-18Initiated BofA/Merrill Buy $56
Apr-02-18Downgrade Evercore ISI Outperform → In-line
Feb-22-18Downgrade Jefferies Buy → Hold
Feb-19-20 04:01PM  Alkermes to Present at the 9th Annual SVB Leerink Global Healthcare Conference PR Newswire +6.02%
Feb-18-20 11:18PM  Edited Transcript of ALKS earnings conference call or presentation 13-Feb-20 1:00pm GMT Thomson Reuters StreetEvents
Feb-14-20 10:49AM  Alkermes' (ALKS) Earnings and Revenues Beat Estimates in Q4 Zacks
10:46AM  Alkermes Reported More Revenue Than Expected. Heres Why the Stock Is Falling. Barrons.com
Feb-13-20 09:32AM  Alkermes (ALKS) Tops Q4 Earnings and Revenues Beat Estimates Zacks -7.59%
09:05AM  Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates Zacks
08:05AM  The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO Benzinga
07:00AM  Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020 PR Newswire
05:00AM  Alkermes Targets Bipolar Disorder and Schizophrenia MoneyShow
Feb-10-20 09:28AM  Alkermes (ALKS) to Report Q4 Earnings: What's in Store? Zacks
Feb-06-20 04:00PM  Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results PR Newswire
12:30PM  Alkermes (ALKS) to Report Q4 Results: Wall Street Expects Earnings Growth Zacks
Jan-29-20 09:54AM  Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review Zacks
Jan-28-20 07:00AM  Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder PR Newswire
Jan-16-20 05:50PM  Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-13-20 09:40AM  Hedge Fund Favorites vs. Alkermes Plc (ALKS) In 2019 Insider Monkey
05:11AM  Does Alkermes plc (NASDAQ:ALKS) Have A High Beta? Simply Wall St.
Jan-10-20 05:50PM  Alkermes (ALKS) Gains As Market Dips: What You Should Know Zacks
Jan-08-20 04:00PM  Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-06-20 11:40AM  LGND vs. ALKS: Which Stock Is the Better Value Option? Zacks
Dec-30-19 10:23AM  Alnylam Stock Up More Than 61% YTD on Pipeline Progress Zacks
09:44AM  Flexion's (FLXN) Stock Up on FDA Approval for Zilretta sNDA Zacks
Dec-26-19 07:22AM  New Strong Buy Stocks for December 26th Zacks
Dec-24-19 01:12PM  Seattle Genetics Submits NDA to FDA for Tucatinib Combo Zacks
Dec-20-19 05:50PM  Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know Zacks
12:00PM  All You Need to Know About Alkermes (ALKS) Rating Upgrade to Strong Buy Zacks
09:28AM  Bausch's (BHC) Arazlo Gets FDA Approval for Acne Vulgaris Zacks
08:27AM  Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib Zacks
08:13AM  New Strong Buy Stocks for December 20th Zacks
Dec-19-19 08:59AM  5 Losing Stocks From 2019 to Rebound Next Year Zacks
Dec-18-19 08:50AM  Alnylam's Kidney Disease Drug Succeeds in Late Stage Study Zacks
07:59AM  5 Beaten-Down Biotech Stocks Set to Rebound in 2020 Zacks
Dec-17-19 10:25AM  Mallinckrodt Initiates Phase IV Study on Acthar for Keratitis Zacks
09:59AM  The Zacks Analyst Blog Highlights: Baidu, Alkermes, Commvault Systems, Veoneer and Zuora Zacks
Dec-16-19 03:55PM  5 Health Care Stocks Gurus Are Buying GuruFocus.com
09:46AM  Horizon Therapeutics Eye Drug Gets Positive FDA Advisory Vote Zacks
08:06AM  These 5 Loser Stocks of 2019 Could be Big Winners in 2020 Zacks
08:05AM  Biogen's Gosuranemab Fails in Phase II Brain Disorder Study Zacks
Dec-13-19 08:33AM  Momenta Pharmaceuticals (MNTA) Catches Eye: Stock Jumps 7.1% Zacks
Dec-12-19 09:36AM  Amgen's Osteoporosis Drug Evenity Gets Approval in Europe Zacks
09:10AM  Proteostasis Therapeutics (PTI) in Focus: Stock Moves 7.3% Higher Zacks
Dec-11-19 12:12PM  FDA told Alkermes to stop publishing Vivitrol ad MarketWatch
12:03PM  UPDATE 1-FDA issues warning letter to Alkermes over opioid addiction treatment ad Reuters
11:25AM  FDA issues warning letter to Alkermes over opioid addiction treatment ad Reuters
Dec-10-19 09:26AM  TG Therapeutics' Shares Soar on Positive Early-Stage Data Zacks
Dec-09-19 04:31PM  Regeneron Reports Initial Data for Multiple Myeloma Drug Zacks
04:03PM  bluebird Reports Positive Top-Line Data on Myeloma Drug Zacks
Dec-08-19 07:52AM  Should You Be Pleased About The CEO Pay At Alkermes plc's (NASDAQ:ALKS) Simply Wall St.
Dec-06-19 09:26AM  Sage Therapeutics' Depression Drug Fails in Study, Stock Down Zacks
09:17AM  Hedge Funds Are Warming Up To Alkermes Plc (ALKS) Insider Monkey
Dec-05-19 10:02AM  Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug Zacks
09:07AM  Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon Zacks
Dec-04-19 10:10AM  AstraZeneca Sells Schizophrenia Drug Rights in US and Canada Zacks
09:29AM  Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 6.4% in Session Zacks
Dec-03-19 03:18PM  Epizyme Announces FDA Committee Review of Tazemetostat NDA Zacks
09:16AM  Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU Zacks
08:29AM  Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 10.1% Zacks
Nov-29-19 09:26AM  Global Blood (GBT) in Focus: Stock Moves 5.2% Higher Zacks
09:13AM  BioDelivery's Belbuca Sales & Symproic Addition Encouraging Zacks
Nov-27-19 08:52AM  ChemoCentryx Up on Encouraging Rare Disease Candidate Data Zacks
Nov-26-19 08:36AM  Myovant (MYOV) Catches Eye: Stock Jumps 6.7% Zacks
08:24AM  Intercept's (ICPT) NDA for NASH Drug Gets Priority Review Zacks
Nov-25-19 09:18AM  Alexion Gets Approval for Label Expansion of Soliris in Japan Zacks
07:00AM  Alkermes Completes Acquisition of Rodin Therapeutics PR Newswire
Nov-22-19 09:45AM  Biogen Ends Enrollment in Eye Disorder Study on Gene Therapy Zacks
09:31AM  Alkermes (ALKS) Up 3% Since Last Earnings Report: Can It Continue? Zacks
Nov-21-19 10:24AM  Vertex (VRTX) Gets French Reimbursement for CF Drug Orkambi Zacks
09:54AM  Alnylam's Givosiran Gets FDA Nod for Acute Hepatic Porphyria Zacks
09:01AM  Alnylam (ALNY) Catches Eye: Stock Jumps 10.5% Zacks
Nov-20-19 09:41AM  Editas Medicine (EDIT) in Focus: Stock Moves 7.8% Higher Zacks
09:31AM  Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More Zacks
09:30AM  Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug Zacks
Nov-19-19 09:36AM  Alkermes to Acquire Rodin Therapeutics, Boost CNS Pipeline Zacks
09:26AM  Protalix Finalizes Accelerated Approval Pathway for PRX-102 Zacks
07:00AM  Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder PR Newswire
Nov-18-19 05:25PM  Celgene's Revlimid-Rituximab Combo Gets Positive CHMP Opinion Zacks
08:22AM  Struggling drugmaker Alkermes buys Boston biotech American City Business Journals
07:30AM  Alkermes to acquire Rodin Therapeutics for up to $950 million MarketWatch
07:00AM  Alkermes to Acquire Rodin Therapeutics PR Newswire
Nov-15-19 10:02AM  VistaGen's (VTGN) Major Depressive Disorder Drug Disappoints Zacks +5.37%
08:57AM  Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal Zacks
Nov-14-19 03:08PM  Biogen shares fall 3% MarketWatch
10:20AM  BioDelivery (BDSI) Stock Up on Q3 Earnings Beat & Raised View Zacks
Nov-13-19 09:23AM  Top Ranked Momentum Stocks to Buy for November 13th Zacks
09:05AM  Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss Zacks
08:00AM  IVERIC bio (ISEE) Q3 Loss Narrows Y/Y, Zimura Advancing Well Zacks
Nov-12-19 04:01PM  Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences PR Newswire
09:52AM  Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat Zacks
07:00AM  Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY PR Newswire
Nov-08-19 02:33PM  Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates Zacks
10:08AM  Spectrum Pharma's (SPPI) Q3 Loss Narrows, Focus on Rolontis Zacks
10:00AM  Global Blood's (GBT) Q3 Loss Widens, Voxelotor in Focus Zacks
09:32AM  Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up Zacks
08:56AM  Arena Pharmaceuticals' (ARNA) Q3 Loss Widens, Revenues Beat Zacks
08:14AM  The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut Benzinga
07:00AM  Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting PR Newswire
Nov-07-19 02:30PM  7 Stocks the Vanguard Health Care Fund Keeps Buying GuruFocus.com
11:53AM  Biotech Stock On The Radar: Alkermes At A Crossroads Benzinga
11:08AM  Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales Zacks
11:05AM  Horizon Therapeutics' (HZNP) Q3 Earnings Beat Estimates Zacks
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. It also has a clinical research collaboration with Fred Hutchinson Cancer Research Center for ALKS 4230, Alkermes' immuno-oncology drug candidate to expand tumor-killing immune cells and to avoid activation of immunosuppressive cells. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
POPS RICHARD FDirector and CEO, Alkermes plcFeb 17Option Exercise0.008,7500735,236Feb 18 04:12 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 17Option Exercise0.003,0000191,497Feb 18 04:11 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 17Option Exercise0.002,500053,253Feb 18 04:09 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 17Option Exercise0.003,000063,459Feb 18 04:07 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 17Option Exercise0.002,500034,452Feb 18 04:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 16Option Exercise0.0018,1250734,558Feb 18 04:12 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerFeb 16Option Exercise0.003,375010,252Feb 18 04:10 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 16Option Exercise0.003,3750188,497Feb 18 04:11 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 16Option Exercise0.003,375051,925Feb 18 04:09 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 16Option Exercise0.003,375061,631Feb 18 04:07 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 16Option Exercise0.002,375032,777Feb 18 04:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 14Option Exercise9.21100,000921,000816,433Nov 15 04:08 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 14Sale19.50100,0001,950,000716,433Nov 15 04:08 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 13Option Exercise9.2120,000184,200205,122Nov 15 04:07 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 13Sale19.7020,000394,056185,122Nov 15 04:07 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 08Option Exercise9.2130,205278,188746,638Nov 08 04:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 08Sale19.7330,205595,827716,433Nov 08 04:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 07Option Exercise9.2169,795642,812786,228Nov 08 04:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 07Sale19.8169,7951,382,618716,433Nov 08 04:06 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 06Option Exercise9.2120,000184,200205,122Nov 08 04:04 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 06Sale19.7620,000395,116185,122Nov 08 04:04 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 19Option Exercise9.21100,000921,000816,433Sep 23 06:16 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 19Sale21.54100,0002,153,550716,433Sep 23 06:16 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSSep 13Option Exercise11.7420,000234,80058,256Sep 17 07:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 12Option Exercise9.21100,000921,000816,433Sep 13 05:20 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 12Sale22.68100,0002,268,220716,433Sep 13 05:20 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 05Option Exercise9.21100,000921,000816,433Sep 06 05:01 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 05Sale20.18100,0002,017,830716,433Sep 06 05:01 PM
MITCHELL PAUL JDirectorJul 01Option Exercise8.987,00062,8607,000Jul 02 06:24 PM
Hopkinson Craig C.SVP, Med Dev/Med Affairs, CMOJun 07Option Exercise0.001,25007,245Jun 10 05:13 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 23Option Exercise8.5550,000427,500766,433May 24 08:09 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 23Sale24.2250,0001,211,150716,433May 24 08:09 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 22Option Exercise8.5520,000171,000205,122May 23 05:50 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 22Sale24.9320,000498,532185,122May 23 05:50 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 16Option Exercise8.5560,000513,000776,433May 24 08:09 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 16Sale25.4260,0001,525,278716,433May 24 08:09 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 09Option Exercise8.557,00059,85053,923May 13 05:54 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 09Sale26.895,373144,49848,550May 13 05:54 PM
Robinson James A. Jr.President & COO,Alkermes, Inc.Apr 04Option Exercise0.006,25006,250Apr 05 05:10 PM
MITCHELL PAUL JDirectorApr 01Option Exercise8.981,0008,9801,000Apr 02 07:00 PM
MITCHELL PAUL JDirectorApr 01Sale36.641,00036,6400Apr 02 07:00 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 14Option Exercise8.5525,000213,750210,122Mar 14 06:53 PM
Wysenski NancyDirectorMar 14Buy33.0644514,7124,302Mar 18 05:05 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 14Sale33.0525,000826,373185,122Mar 14 06:53 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 13Option Exercise8.5515,829135,338732,262Mar 14 06:38 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 13Sale33.5115,829530,485716,433Mar 14 06:38 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 12Option Exercise8.5544,171377,662760,604Mar 14 06:38 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 12Sale33.2444,1711,468,447716,433Mar 14 06:38 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 07Option Exercise8.5520,000171,000205,122Mar 07 06:20 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 07Sale32.0720,000641,362185,122Mar 07 06:20 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 05Option Exercise8.5550,000427,500766,433Mar 07 06:16 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 05Sale33.6350,0001,681,740716,433Mar 07 06:16 PM
MITCHELL PAUL JDirectorMar 01Option Exercise8.981,0008,9801,000Mar 04 05:13 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 01Option Exercise0.0017,5000724,203Mar 04 05:53 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 01Option Exercise0.004,5000186,445Mar 04 05:50 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 01Option Exercise0.002,250047,585Mar 04 05:45 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 01Option Exercise0.004,500051,044Mar 04 05:35 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 01Option Exercise0.002,250031,064Mar 04 05:27 PM
MITCHELL PAUL JDirectorMar 01Sale33.481,00033,4800Mar 04 05:13 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 26Option Exercise0.0010,0000710,590Feb 27 05:20 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 26Option Exercise0.002,6250182,717Feb 27 05:18 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 26Option Exercise0.001,100045,659Feb 27 05:15 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 26Option Exercise0.002,625047,316Feb 27 05:12 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 26Option Exercise0.001,100029,138Feb 27 05:08 PM
open in yahoo | open in reuters | open in google